"The Institute of Clinical Pharmacology of Suzhou Industrial Technology Research Institute (SITRI), also known as Suzhou Sizui Institute of Clinical Pharmacology, is a new research and development organization that focuses on the key technologies of clinical pharmacology and translational medicine, and is jointly established by Suzhou Industrial Technology Research Institute (SITRI) and Taicang Municipal Government, in cooperation with Suzhou Biyi. It is a new type of research and development organization that focuses on key clinical pharmacology technologies and translational medicine.
       The Institute will gather global clinical research technologies, projects and talents to build a clinical research system of international level, and provide one-stop nanny service for the whole chain, including: key technologies of clinical pharmacology and translational medicine research, integration and expansion of clinical resources, co-construction of bases and featured bases and strategic cooperation, and governmental and public affairs. Public Affairs.

       At present, the Institute has established GCP bases with six hospitals, including the First Affiliated Hospital of Soochow University, Jiangsu Provincial Hospital of Traditional Chinese Medicine, and the First Affiliated Hospital of Nanchang University; long-term clinical research partnerships with five hospitals, including the Fifth Central Hospital of Tianjin and the Ganzhou Municipal People's Hospital; the Clinical Center for Specialty Drugs for Inhalation and Nebulization with Suzhou Municipal Hospital; and the research-based clinical hospital with Nanjing Medical University.

       Shanghai Azure Deep Show is a specialized and high standard SMO company. Headquartered in Shanghai, the company has more than 170 stable and professional clinical study coordinators, with business covering more than 20 cities in China. Service scope: clinical research coordinator dispatch, subject recruitment, center quick start, quality control audit.

       The company has formed long-term cooperative relationships with more than 50 hospitals nationwide, while providing Phase I ward construction and management services for many hospitals in the Yangtze River Delta, Pearl River Delta, Beijing-Tianjin-Hebei and Chengdu-Chongqing regions, forming unique service characteristics. The company has won the praise of customers with its professional, standardized, honest and efficient working mode. The team is rigorous and meticulous, constantly enterprising, and is committed to enhancing the life and health of the people.

       Suzhou Xicui is a company focusing on providing professional, high-quality and efficient preclinical DMPK and biological sample analysis and testing services for pharmaceutical R&D units. Our service scope: small molecule drug, large molecule drug DMPK and biological sample analysis and testing services.

       The company has established a technical platform for preclinical and clinical biospecimen testing, in vivo and ex vivo pharmacokinetic testing and evaluation in accordance with the GLP/GCLP system, and has obtained the CMA certification for the qualification of inspection and testing organizations and the capacity certification of the China Academy of Inspection and Quarantine (CAIQ).

       The technical team has rich project experience in antibody-coupled drugs, nucleic acid drugs, nano-drugs, liposomal drugs, inhalation drugs and other special drug varieties, and has completed 60+ preclinical DMPK declaration projects and 150+ clinical biosample analysis projects.